PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12324655-2 2002 The in vitro response of cells of the B lineage (CD19(+)) from the marrow of 22 adult subjects to glucocorticoids was evaluated herein using both natural steroids and dexamethasone (Dex). Dexamethasone 167-180 CD19 molecule Homo sapiens 49-53 12324655-3 2002 When exposed to 1 micro M Dex, 32% of the subjects exhibited high losses of CD19(+) B cells in the range of 45%. Dexamethasone 26-29 CD19 molecule Homo sapiens 76-80 34753229-9 2021 When CD19 CAR-T cells were co-cultured with different tumor cells, the proportion and average MFI of CD19 CAR-T cells showed that the proliferation inhibition of dexamethasone was higher than that of methylprednisolone. Dexamethasone 162-175 CD19 molecule Homo sapiens 5-9 34857478-8 2022 The effect of dexamethasone (DEX) or hydroxychloroquine (HCQ) treatment on the proportion of CD19+Siglec-10+ B cells in PBMCs from SLE patients was also determined. Dexamethasone 14-27 CD19 molecule Homo sapiens 93-97 34857478-8 2022 The effect of dexamethasone (DEX) or hydroxychloroquine (HCQ) treatment on the proportion of CD19+Siglec-10+ B cells in PBMCs from SLE patients was also determined. Dexamethasone 29-32 CD19 molecule Homo sapiens 93-97 34753229-9 2021 When CD19 CAR-T cells were co-cultured with different tumor cells, the proportion and average MFI of CD19 CAR-T cells showed that the proliferation inhibition of dexamethasone was higher than that of methylprednisolone. Dexamethasone 162-175 CD19 molecule Homo sapiens 101-105 34753229-11 2021 Conclusion: Dexamethasone inhibits the cell proliferation of CD19 CAR-T cells more than methylprednisolone during the targeting of different tumor cell lines. Dexamethasone 12-25 CD19 molecule Homo sapiens 61-65 34753229-12 2021 The inhibition effect of dexamethasone on the proliferation and amplification of CD19 CAR-T cells was greater than that of methylprednisolone during the targeting of CD19 CAR-T cells to different tumor cell lines. Dexamethasone 25-38 CD19 molecule Homo sapiens 81-85 34753229-12 2021 The inhibition effect of dexamethasone on the proliferation and amplification of CD19 CAR-T cells was greater than that of methylprednisolone during the targeting of CD19 CAR-T cells to different tumor cell lines. Dexamethasone 25-38 CD19 molecule Homo sapiens 166-170 33974586-2 2022 Several B-cell abnormalities have been described in ITP pathogenesis.This study assessed the effects of high-dose dexamethasone (HD-DXM) on the percentages and absolute counts of CD19+CD24hiCD38hi regulatory (Bregs) and CD19+CD27+ memory B lymphocytes (Bmems) in children with chronic ITP during active bleeding.The study was a prospective cross-section case-control, included 20 children with chronic ITP and uncontrolled bleeding. Dexamethasone 114-127 CD19 molecule Homo sapiens 179-183 33974586-2 2022 Several B-cell abnormalities have been described in ITP pathogenesis.This study assessed the effects of high-dose dexamethasone (HD-DXM) on the percentages and absolute counts of CD19+CD24hiCD38hi regulatory (Bregs) and CD19+CD27+ memory B lymphocytes (Bmems) in children with chronic ITP during active bleeding.The study was a prospective cross-section case-control, included 20 children with chronic ITP and uncontrolled bleeding. Dexamethasone 114-127 CD19 molecule Homo sapiens 220-224 28696805-8 2018 In RA patient with active extra-articular involvement, intracellular dexamethasone level (IDL) in lymphocytes diminished with expansion of P-gp+CXCR4+ CD19+ B cells. Dexamethasone 69-82 CD19 molecule Homo sapiens 151-155 31439679-4 2020 Compared to other cell types, CD19+/B and CD56+/NK cells were more sensitive to dexamethasone, venetoclax and midostaurin, while monocytes were more sensitive to trametinib. Dexamethasone 80-93 CD19 molecule Homo sapiens 30-34 33424835-6 2020 We further treated this patient with CD19hsCAR-T following chemotherapy with Vindesine, Idarubicin, Dexamethasone, and Pegylated Asparaginase (VDLD) plus bortezomib. Dexamethasone 100-113 CD19 molecule Homo sapiens 37-48 15153534-4 2004 Surprisingly, we found that incubation of unfractionated PBMC with IL-15 for 48 h resulted in the inhibition of glucocorticoid receptor (GCR) nuclear translocation in response to dexamethasone (DEX) treatment in CD19-positive B cells significantly greater than CD19-negative non-B cells (p < 0.01). Dexamethasone 179-192 CD19 molecule Homo sapiens 212-216 17310380-0 2007 The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Dexamethasone 14-27 CD19 molecule Homo sapiens 109-113 15153534-4 2004 Surprisingly, we found that incubation of unfractionated PBMC with IL-15 for 48 h resulted in the inhibition of glucocorticoid receptor (GCR) nuclear translocation in response to dexamethasone (DEX) treatment in CD19-positive B cells significantly greater than CD19-negative non-B cells (p < 0.01). Dexamethasone 179-192 CD19 molecule Homo sapiens 261-265 15153534-4 2004 Surprisingly, we found that incubation of unfractionated PBMC with IL-15 for 48 h resulted in the inhibition of glucocorticoid receptor (GCR) nuclear translocation in response to dexamethasone (DEX) treatment in CD19-positive B cells significantly greater than CD19-negative non-B cells (p < 0.01). Dexamethasone 194-197 CD19 molecule Homo sapiens 212-216 19147788-7 2009 Furthermore, these CD133(+)/CD19(-) ALL cells were more resistant to treatment with dexamethasone and vincristine, key components in childhood ALL therapy, than the bulk leukemia population. Dexamethasone 84-97 CD19 molecule Homo sapiens 28-32 15153534-4 2004 Surprisingly, we found that incubation of unfractionated PBMC with IL-15 for 48 h resulted in the inhibition of glucocorticoid receptor (GCR) nuclear translocation in response to dexamethasone (DEX) treatment in CD19-positive B cells significantly greater than CD19-negative non-B cells (p < 0.01). Dexamethasone 194-197 CD19 molecule Homo sapiens 261-265 12467941-8 2002 Changes in cell redistribution (CD4(+), CD8(+), CD19(+), CD56(+) and HLADR(+) cells) after DEX administration were more prominent in controls than in patients, but the effects of DEX varied dependent on whether patients exhibited DEX-induced suppression of cortisol secretion. Dexamethasone 91-94 CD19 molecule Homo sapiens 48-52